Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from June 2023.
Drug Pricing
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy -
Read more: Public Health Product Hops Public Health Product Hops
Are there circumstances for which allowing a product hop resulted in a net benefit to society that exceeded the excess costs associated with the new product?
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from December 2022.
-
Read more: HHS’ New Prescription Drug and Health Care Spending Rule HHS’ New Prescription Drug and Health Care Spending Rule
A new interim final rule requires health insurance plans and issuers on the marketplace to report data on prescription drug and health care spending.
-
Read more: What Democrats’ Drug Pricing Plan Means for Consumers What Democrats’ Drug Pricing Plan Means for Consumers
The new drug pricing plan creates protections against out-of-pocket costs for seniors with Medicare Part D benefits and people who take insulin.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of September 2021.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of May 2021.
-
Read more: New Rule Might Increase Out-of-Pocket Drug Costs for Patients New Rule Might Increase Out-of-Pocket Drug Costs for Patients
Patients may face increased out-of-pocket drug costs as a result of a rule finalized by the Centers for Medicare & Medicaid Services in July 2020.
-
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Topics range from an analysis of recent developments in drug-pricing transparency, to an analysis of state-level drug product selection laws.
